Acute Disseminated Encephalomyelitis (ADEM)

Article Author:
Arayamparambil Anilkumar
Article Author (Archived):
Lisa Foris
Article Editor:
Prasanna Tadi
Updated:
9/28/2019 4:01:29 PM
PubMed Link:
Acute Disseminated Encephalomyelitis (ADEM)

Introduction

Acute disseminated encephalomyelitis (ADEM), also referred to as postinfectious encephalomyelitis, is an acute, rapidly progressive, autoimmune process that occurs in the central nervous system. ADEM is characterized by demyelination in the brain and spinal cord (and occasionally the optic nerve), as a result of inflammation that occurs in response to a preceding infection or immunization.[1][2]

Etiology

ADEM has been associated with some infectious organisms and immunizations. Most commonly associated organisms include cytomegalovirus, Epstein-Barr virus, herpes simplex virus, human herpes-virus-6, influenza virus, hepatitis A, human immunodeficiency virus, and mycoplasma pneumonia – though, in the majority of cases, the causative pathogen is not identified. Additional associated bacterial infections include Leptospira, beta-hemolytic streptococci, and Borrelia burgdorferi.[3][4][5] Prior to the development of immunization programs, ADEM was most commonly associated with measles (in addition to an increased incidence in association with rubeola, rubella, mumps, varicella, and smallpox as well). Today, ADEM is more commonly associated with viral infections of the gastrointestinal or respiratory tracts.

Rabies (Semple) vaccine has been the earliest reported vaccine-associated with ADEM. It is seen in both adults and children approximately eight to 21 days following immunization. Other less commonly associated vaccines include those for measles, pertussis, tetanus, influenza, hepatitis B, diphtheria, rubella, pneumococcus, varicella, smallpox, human papillomavirus, and poliomyelitis.

Epidemiology

Although it is a rare illness, there is an estimated 1 in 125,000-250,000 individuals affected by ADEM each year. Though most cases occur in children (majority younger than age ten, and the remainder between the ages ten to 20), ADEM has been documented in adults ranging from ages 18-82 as well. The disease occurs more commonly in males than in females (male to female ratio 1.3:1), and more often seasonally in the winter and spring (historically, the colder months of the year).

The risk of developing ADEM depends on some factors including an individual’s genetics, exposure to infectious organisms, immunization exposure, and lighter skin pigmentation. All ethnic groups are susceptible to developing ADEM, and the condition occurs worldwide.

In 50% - 75% of cases, ADEM is associated with either a preceding infection or vaccination, and the majority of cases follow a viral or bacterial infection (although the causative pathogen is not always identified).

Pathophysiology

The exact mechanism of ADEM is not completely understood, but it is thought to result from inflammation triggered by an environmental stimulus (e.g., vaccination or infectious disease) in genetically susceptible individuals. ADEM has been further characterized as an autoimmune disorder causing demyelination in the central nervous system (CNS). 

It has been proposed that either a cell-mediated response or antibodies produced in response to an environmental trigger cross-react with myelin autoantigens (e.g., myelin basic protein, myelin oligodendrocyte protein, proteolipid protein) in the CNS, resulting in the demyelination characteristically seen in ADEM. [6] An alternatively proposed mechanism suggests that ADEM may occur as a result of increased vascular permeability and congestion in the CNS due to the inflammation and circulating immune complexes that follow vaccination or infection. Mononuclear infiltration of the vasculature of the CNS is thought to result in edema surrounding vessels and, at times, hemorrhage causing damage to surrounding neuronal cells (e.g., demyelination, necrosis or gliosis) and ultimately, the variety of possible clinical presentations and prognoses seen in individuals with ADEM. The inflammation and increased vascular permeability associated with ADEM has also been proposed as a mechanism by which breakdown of the blood-brain-barrier occurs, allowing infiltration of the CNS by both antigens and inflammatory cells involved in the concomitant cell-mediated immune response.

History and Physical

ADEM is classically seen following an illness (or less frequently, a vaccination) with a lag time ranging from a few days to up to 60 days (mean is 26 days). Although in about 25% of affected individuals, there may not be an obvious preceding event. The onset of ADEM is acute and rapidly progressive, and it is characterized by multifocal neurologic symptoms that require early hospitalization.

Some non-specific (e.g., constitutional) symptoms associated with ADEM include fever, headache, fatigue, malaise, nausea, and vomiting. In approximately 20% - 52% of cases in adults, there may be associated with altered mental status (encephalopathy), which may involve irritability, confusion, psychosis, somnolence, or even coma. In addition to motor and sensory deficits (e.g., paraparesis, tetraparesis), patients may also present with brainstem deficits (e.g., dysarthria or oculomotor dysfunction), or other neurologic abnormalities (e.g., seizures, meningismus, ataxia, aphasia, nystagmus, optic neuritis, urinary retention, elevated intracranial pressure, or extrapyramidal signs).

Some adults with ADEM may also develop signs of peripheral nervous system involvement which are defined by abnormalities on electrodiagnostic testing. Signs and symptoms of peripheral involvement may include paresthesia or anesthesia of the limbs or muscle atrophy.

Patients with ADEM presenting with peripheral involvement have been seen to have a worse prognosis and increased risk of relapse compared to those with only CNS involvement.

Evaluation

The imaging modality of choice for evaluating ADEM is MRI. It demonstrates hyperintense lesions on T2-weighted, fluid-attenuated inversion recovery (FLAIR), proton-density, and echo-planar trace diffusion MRI sequences. Lesions are not typically visualized on T1-weighted sequences, though larger lesions may appear as hypointensities. Imaging of ADEM may reveal a single lesion (e.g., large or small, confluent, or solitary) or multiple lesions throughout the white (e.g., periventricular and subcortical) and grey (e.g., basal ganglia, thalamus, cortex) matter of the brain – most characteristically seen as multiple, widespread, asymmetric lesions bilaterally throughout the brain. [7][8][9]There may be additional infratentorial lesions in the brainstem, cerebellum, and spinal cord, but these rarely present as isolated lesions without an accompanying lesion in the brain.

ADEM lesions typically present with indistinct margins on imaging. This may help differentiate these lesions from the clear-cut margins typical of the lesions seen in multiple sclerosis.

It is important to note that ADEM may present with a normal MRI, in other words, without any visual evidence of disease (even after multiple scans). In some cases, it is also possible that MRI lesions may appear weeks following the onset of symptoms. Although most MRI lesions resolve within 18 months, repeat imaging is warranted, especially early in the course of the disease, as there may be fluctuations in lesions (e.g., new lesions may appear while older lesions resolve) despite the patient potentially remaining asymptomatic.

Although MRI is the imaging modality of choice, a CT scan may be considered in an urgent setting to rule out any other potentially life-threatening causes of neurological dysfunction. In the case of ADEM, a CT scan is most often unremarkable, especially earlier on in the course of the disease. In later stages, ADEM may appear as focal or multifocal regions of white matter damage on CT. Cerebrospinal fluid (CSF) analysis (e.g., following a lumbar puncture) may reveal abnormalities in 50% - 80% of patients with ADEM. These findings may include lymphocytic pleocytosis (with a white blood cell count of fewer than 100 cells/mL) and a slightly elevated CSF protein (Fewer than 70 mg/dL). More specifically, patients with ADEM are often seen to have an elevated level of cerebrospinal fluid (CSF) myelin basic protein on CSF analysis. This is a sign of demyelination in the CNS.

An EEG done on a patient with ADEM may reveal a disturbed sleep pattern, and either a focal or generalized slowing of electrical activity.

There is no specific biomarker or diagnostic test that establishes a diagnosis of ADEM.  It is, however, considered, when a patient presents with multifocal neurologic deficits without any prior history of neurologic dysfunction. One or more demyelinating lesions (either supra- or infratentorial) on brain MRI will further support a diagnosis of ADEM. These findings, taken together with a history of infection or immunization, as well as abnormal CSF findings, will further support a diagnosis of ADEM (but are not necessary to do so).

Although there are no set diagnostic criteria for ADEM in adults, for children, a diagnosis is made based on the presence of both encephalopathy and multifocal CNS involvement.

Children with ADEM have also been found to have an elevated sedimentation rate and a slightly elevated platelet count.

Treatment / Management

Empiric treatment with acyclovir may be initiated in patients presenting with meningeal signs, fever, acute encephalopathy, and signs of inflammation in either the blood or CSF.

However, the mainstay of treatment for ADEM is immunosuppression with high-dose intravenous glucocorticoids. These can be started simultaneously with acyclovir or antibiotics on the initial patient presentation. [10][11]If a patient is not improving or is responding poorly to glucocorticoid treatment, try intravenous immune globulin (IVIG), plasma exchange, or cyclophosphamide.

Pearls and Other Issues

In adults, ADEM is difficult to differentiate from an initial attack of multiple sclerosis (MS) based on a single clinical encounter or radiographic evidence alone. It is important to diagnose a patient with either condition accurately because the approach to the treatment of the two conditions differs significantly. Though MS is characterized by repeated attacks of neurological dysfunction separated in both time and space, there is a significant overlap between the two conditions regarding CNS symptoms and radiographic evidence. Patients with ADEM are more likely to have a history of prodromal viral illness, along with fever, neck stiffness, ataxia, and impaired consciousness and/or encephalopathy, while MS patients typically do not present with these complaints. Additionally, MS is more often monosymptomatic (e.g., optic neuritis alone) and has a chronic, relapsing, and remitting course.[12][13]

A brain MRI may help distinguish between the two. ADEM typically involves larger, bilateral, asymmetric lesions that are also higher in number than those typically seen with MS. Brain lesions tend to be more well-defined when seen in MS vs. the ill-defined lesions seen in ADEM. MS is more likely to be associated with brain lesions of varying ages while ADEM typically has lesions that are all approximately the same age. Lesions in the thalamus are seen more commonly in ADEM, while periventricular lesions are more common in MS.

Acute hemorrhagic encephalomyelitis (AHEM), or acute hemorrhagic leukoencephalitis, acute necrotizing hemorrhagic leukoencephalitis of Weston-Hurst) is a hyperacute variant of ADEM that rapidly progresses to coma and may be fatal. AHEM is triggered similarly to ADEM, following exposure to an infectious organism or vaccination.  Symptoms of AHEM include asymmetric multifocal neurologic deficits, meningismus, headache, and seizures.[14]

A head CT or MRI of a patient with AHEM may reveal focal hemorrhagic lesions, in addition to edema, petechial and perivascular hemorrhages, vascular destruction and fibrin deposition, and neutrophilic infiltration.

Convergence with other CNS demyelinating disorders and multiphasic presentation:

Other demyelinating disorders like MS, optic neuritis (ON) and neuromyelitis optica spectrum disorders can have overlaps in presentation as well as convergence with ADEM. This has increasingly been recognized and considered in the diagnostic criteria for ADEM. There are multiphasic ADEM cases with an event of ADEM occurring more than 3 months following the initial ADEM diagnosis. [15]

Enhancing Healthcare Team Outcomes

The presentation, diagnosis, and management if ADEM is very complex and best done with a team that includes an infectious disease expert, emergency department physician, pathologist, nurse practitioner, neurologist, psychiatrist, and an intensivist.  ADEM is classically seen following an illness (or less frequently, a vaccination) with a lag time ranging from a few days to up to 60 days (mean is 26 days). Although in about 25% of affected individuals, there may not be an obvious preceding event. The onset of ADEM is acute and rapidly progressive, and it is characterized by multifocal neurologic symptoms that require early hospitalization. The decision to treat with an antiviral agent requires clinical judgment. ICU monitoring of these patients is required and nurses need to provide close monitoring and at the same time provide prophylaxis against DVT, pressure sores and stress ulcers. Any new neurological change must be reported to the team.

The pharmacist should provide medication reconciliation and assist with acyclovir and high-dose intravenous glucocorticoid therapy dosing. If a patient is not improving, the pharmacist may assist in correct dosing and monitoring of intravenous immune globulin (IVIG) or cyclophosphamide. The pharmacist can assist in educating the patient and family in regards to medication compliance.

Specialty trained nurses assist in patient care, administer treatments, aid in the education of patients and their families, and keep the team informed about changes in patient status.

There are rare cases of severe hemorrhagic necrosis leading to rapid progression and death, especially if affecting brainstem. Only through such an interprofessional team approach can the morbidity and mortality of this disorder be lowered.

The outlook of patients with ADEM is otherwise fair to good, but those who present with severe neurological deficits may have residual defects after recovery. The recovery period can take weeks or months. [10][16] [Level V]


References

[1] Essrani R,Essrani RK,Mehershahi S,Lohana AK,Sudhakaran A, Oculomotor Nerve Palsy After Influenza Vaccine in Inflammatory Bowel Disease. Cureus. 2018 Dec 21;     [PubMed PMID: 30820379]
[2] Nishiyama M,Nagase H,Tomioka K,Tanaka T,Yamaguchi H,Ishida Y,Toyoshima D,Fujita K,Maruyama A,Sasaki K,Oyazato Y,Nakagawa T,Takami Y,Nozu K,Nishimura N,Nakashima I,Iijima K, Clinical time course of pediatric acute disseminated encephalomyelitis. Brain     [PubMed PMID: 30833092]
[3] Alves JM,Marques IB,Gil-Gouveia R, [Vaccination Controversies: An Adult Case of Post-Vaccinal Acute Disseminated Encephalomyelitis]. Acta medica portuguesa. 2019 Feb 1;     [PubMed PMID: 30753808]
[4] Rossor T,Benetou C,Wright S,Duignan S,Lascelles K,Robinson R,Das K,Ciccarelli O,Wassmer E,Hemingway C,Lim M,Hacohen Y, Early predictors of epilepsy and subsequent relapse in children with acute disseminated encephalomyelitis. Multiple sclerosis (Houndmills, Basingstoke, England). 2019 Feb 7;     [PubMed PMID: 30730236]
[5] Galetta KM,Bhattacharyya S, Multiple Sclerosis and Autoimmune Neurology of the Central Nervous System. The Medical clinics of North America. 2019 Mar;     [PubMed PMID: 30704684]
[6] Torisu H,Okada K, Vaccination-associated acute disseminated encephalomyelitis. Vaccine. 2019 Feb 14;     [PubMed PMID: 30683508]
[7] Kawanaka Y,Ando K,Ishikura R,Katsuura T,Wakata Y,Kodama H,Takaki H,Takada Y,Ono J,Yamakado K, Delayed appearance of transient hyperintensity foci on T1-weighted magnetic resonance imaging in acute disseminated encephalomyelitis. Japanese journal of radiology. 2019 Jan 22;     [PubMed PMID: 30671706]
[8] Anand KS,Agrawal AK,Garg J,Dhamija RK,Mahajan RK, Spectrum of neurological complications in chikungunya fever: experience at a tertiary care centre and review of literature. Tropical doctor. 2019 Jan 24;     [PubMed PMID: 30678544]
[9] Codjia P,Ayrignac X,Carra-Dalliere C,Cohen M,Charif M,Lippi A,Collongues N,Corti L,De Seze J,Lebrun C,Vukusic S,Durand-Dubief F,Labauge P, Multiple sclerosis with atypical MRI presentation: Results of a nationwide multicenter study in 57 consecutive cases. Multiple sclerosis and related disorders. 2019 Feb;     [PubMed PMID: 30592992]
[10] Bhatt P,Bray L,Raju S,Dapaah-Siakwan F,Patel A,Chaudhari R,Donda K,Bhatt NS,Dave M,Linga VG,Lekshminarayanan A,Patel SV,Billimoria ZC,Zuckerman S,Yagnik P,Singh D, Temporal Trends of Pediatric Hospitalizations with Acute Disseminated Encephalomyelitis in the United States: An Analysis from 2006 to 2014 using National Inpatient Sample. The Journal of pediatrics. 2019 Mar;     [PubMed PMID: 30528761]
[11] Yae Y,Kawano G,Yokochi T,Imagi T,Akita Y,Ohbu K,Matsuishi T, Fulminant acute disseminated encephalomyelitis in children. Brain     [PubMed PMID: 30522797]
[12] VAN BOGAERT L, Post-infectious encephalomyelitis and multiple sclerosis; the significance of perivenous encephalomyelitis. Journal of neuropathology and experimental neurology. 1950 Jul     [PubMed PMID: 15437201]
[13] Young NP,Weinshenker BG,Parisi JE,Scheithauer B,Giannini C,Roemer SF,Thomsen KM,Mandrekar JN,Erickson BJ,Lucchinetti CF, Perivenous demyelination: association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis. Brain : a journal of neurology. 2010 Feb     [PubMed PMID: 20129932]
[14] Mader I,Wolff M,Niemann G,Küker W, Acute haemorrhagic encephalomyelitis (AHEM): MRI findings. Neuropediatrics. 2004 Apr     [PubMed PMID: 15127316]
[15] Pohl D,Alper G,Van Haren K,Kornberg AJ,Lucchinetti CF,Tenembaum S,Belman AL, Acute disseminated encephalomyelitis: Updates on an inflammatory CNS syndrome. Neurology. 2016 Aug 30;     [PubMed PMID: 27572859]
[16] Ramanathan S,Mohammad S,Tantsis E,Nguyen TK,Merheb V,Fung VSC,White OB,Broadley S,Lechner-Scott J,Vucic S,Henderson APD,Barnett MH,Reddel SW,Brilot F,Dale RC, Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. Journal of neurology, neurosurgery, and psychiatry. 2018 Feb;     [PubMed PMID: 29142145]